Akèy › Kansè fwa (Kasinòm epatoselilè) › Pennsylvania › Pittsburgh
Etid klinik pou Kansè fwa (Kasinòm epatoselilè) nan Pittsburgh, PA
15 etid pou Kansè fwa (Kasinòm epatoselilè) ap chèche patisipan nan sit nan ak bò kote Pittsburgh (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Ap rekriteFaz 1
- UPMC Hillman Cancer Center, Pittsburgh
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #32, Pittsburgh
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
Ap rekriteFaz 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Ap rekriteFaz 3
- Research Site, Pittsburgh
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Ap rekriteFaz 1/2
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
Molecular Basis of Pediatric Liver Cancer
Ap rekriteEtid obsèvasyon
- UPMC Children's Hospital of Pittsburgh, Pittsburgh
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
Ap rekriteFaz 2
- Allegheny General Hospital, Pittsburgh
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Ap rekriteFaz 2
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Ap rekriteFaz 1
- Clinical Trial Site, Pittsburgh
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Ap rekriteFaz 2
- UPMC Hillman Cancer Center, Pittsburgh
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Ap rekriteFaz 2
- UPMC Hillman Cancer Center, Pittsburgh
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
Ap rekriteFaz 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
Ap rekriteFaz 2
- UPMC Hillman Cancer Center, Pittsburgh
Etid Kansè fwa (Kasinòm epatoselilè) nan lòt vil
- Houston, TX31 etid
- New York City, NY24 etid
- Dallas, TX19 etid
- Los Angeles, CA19 etid
- Boston, MA18 etid
- Cleveland, OH18 etid
- Philadelphia, PA16 etid
- Chicago, IL16 etid
- San Francisco, CA14 etid
- Orange, CA14 etid
- Jacksonville, FL14 etid
- San Antonio, TX13 etid
Lòt etid nan Pittsburgh
- Kansè Poumon ki pa ti selil48 etid
- Kansè (tout kalite)41 etid
- Kansè nan tete39 etid
- Kansè kolorektal32 etid
- Kansè Metastatik31 etid
- Melanom31 etid
- Kansè ovè30 etid
- Kansè Endomèt23 etid
- Kansè pwostat23 etid
- Kansè poumon23 etid
- Karsinòm selil skuamèz tèt ak kou22 etid
- Akidan serebavaskilè22 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.